Browse the evidence

Dietary supplementation with omega-3 polyunsaturated fatty acids (specifically DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing betacellulin (BTC) expression, thereby inhibiting hepatic stellate cell proliferation and collagen production.

To support liver health and potentially reduce fibrosis risk, prioritize dietary sources of Docosahexaenoic Acid (DHA), a type of Omega-3 fatty acid. Research suggests DHA is particularly effective at suppressing betacellulin, a protein that drives liver scarring. While general Omega-3s help, DHA appears to have a stronger specific effect on this pathway. Consult a healthcare provider before making significant dietary changes, especially if you have existing liver conditions.

Dual activation of GPR10 and NPFF2 receptors by lipidated PrRP31 metabolites produces robust, long-acting weight loss in diet-induced obese mice, whereas GPR10-selective activation does not.

This research suggests that for obesity treatment, targeting both GPR10 and NPFF2 receptors simultaneously may be more effective than targeting GPR10 alone. The study used lipidated peptides in mice, showing significant weight loss. This is preclinical data and not a direct human treatment recommendation yet.

Obstructive Sleep Apnea (OSA) is an independent risk factor for the development of Type 2 Diabetes (T2DM) and MASLD, primarily through mechanisms of intermittent hypoxia, sympathetic hyperactivity, and inflammation, rather than solely through obesity.

Treating sleep apnea is not just about feeling rested; it is a critical step in preventing diabetes and liver disease. The lack of oxygen during sleep triggers stress hormones and inflammation that damage metabolism.

Pioglitazone administration reverses hyperglycemia and restores beta-cell maturity markers (increased insulin/Nkx6.1, decreased Aldh1a3) in diabetic db/db mice, while promoting a 'browning' gene expression profile (UCP-1, Cidea) in white adipose tissue.

Pioglitazone effectively lowers blood glucose and improves beta-cell function in insulin-resistant individuals, even if it causes some weight gain. This gain is largely subcutaneous and correlates with improved metabolic health. It also promotes 'browning' markers in fat tissue, suggesting enhanced metabolic flexibility.

Chronic administration of the dual beta-2/beta-3 adrenergic agonist ATR-127 significantly reduces body weight and fat mass while improving glucose homeostasis in diet-induced obese mice, without causing cardiac hypertrophy.

This research suggests that a specific drug targeting fat and muscle metabolism (ATR-127) can reduce body fat and improve blood sugar control in obese individuals without harming the heart, a common side effect of older weight-loss drugs. This is currently only proven in mice and lab cells, so it is not yet available for human use.

Post-exercise cold water immersion (CWI) attenuates resistance training-induced muscle hypertrophy compared to resistance training alone.

If your main goal is building maximum muscle size, avoid cold water immersion immediately after your resistance training sessions. The evidence suggests that cooling the muscles right after lifting blunts the biological signals (like protein synthesis and mTOR signaling) required for growth. If you must use CWI for recovery, schedule it at least several hours away from your training or on rest days to minimize interference with hypertrophy.

Targeting specific protein posttranslational modifications (PTMs) such as phosphorylation, ubiquitination, and acetylation offers therapeutic potential for metabolic diseases including diabetes, obesity, and NAFLD by modulating insulin signaling, glucose metabolism, and inflammatory pathways.

This paper suggests that future treatments for metabolic diseases may target specific molecular switches (PTMs) in your cells. While you cannot directly 'dose' these switches, understanding them explains why current drugs (like SGLT-2 inhibitors or GLP-1 agonists) are effective and why lifestyle changes (diet/exercise) that influence these pathways (e.g., AMPK activation) are beneficial. Consult a doctor about emerging therapies targeting these pathways.

Use of GLP-1 receptor agonists (semaglutide and tirzepatide) is associated with an increased risk of alopecia, potentially mediated by rapid weight loss-induced telogen effluvium or direct receptor interaction in hair follicles.

If you are taking semaglutide or tirzepatide and notice increased hair shedding, do not panic. This is likely telogen effluvium caused by rapid weight loss or metabolic stress, which is usually reversible. Ensure you are eating enough protein and nutrients. Talk to your doctor; they may adjust your plan or provide reassurance, but stopping the medication abruptly is rarely necessary unless the shedding is severe.

The presence of satellite cells reduces ex vivo skeletal muscle force production specifically during the morning, whereas this effect is absent in the afternoon.

If you are training for maximum force output, be aware that your muscles may naturally produce less force in the morning due to circadian regulation. This is not a sign of weakness, but a biological rhythm. If possible, schedule heavy strength training in the afternoon when this circadian suppression is absent.

The reduced force production in the morning associated with satellite cells results in significantly less contractile injury (force loss and dystrophin-negative fibers) following eccentric exercise.

Eccentric exercise causes damage, but the extent of damage varies by time of day. Morning training with satellite cells present may result in less structural damage (dystrophin loss) than afternoon training, potentially due to lower force generation. This suggests morning might be a safer time for high-intensity eccentric work if injury prevention is the goal.

The reduced force production in the morning is mechanistically linked to lower calcium availability for contractile units, as indicated by reduced caffeine-induced contracture force.

This is a basic science finding. It suggests that the reason morning muscles might be weaker is not just neural, but involves how much calcium is available to trigger contraction. This is not directly actionable for training but informs future research on timing.

GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.

For people with schizophrenia, GLP-1 medications are safe and help with weight gain caused by antipsychotics, but they do not treat the psychosis itself. Do not expect them to improve hallucinations or cognitive function. They are a tool for metabolic health, not psychiatric symptom management in this population.

Tirzepatide significantly reduces urine albumin-to-creatinine ratio (UACR) compared to placebo and insulin, indicating improved renal microvascular health, while maintaining a neutral effect on estimated glomerular filtration rate (eGFR) over short-term follow-up.

If you have Type 2 Diabetes or obesity, Tirzepatide (5-15 mg weekly) significantly lowers albuminuria (a marker of kidney stress) compared to placebo or insulin, without negatively impacting your kidney's filtration rate over 6-18 months. This suggests renal protection, particularly for those with existing high albuminuria. However, long-term data is still needed.

Combining GIPR agonism or antagonism with GLP-1 R agonism produces synergistic weight loss in preclinical models, whereas GIPR signaling is not required for this synergy in humans.

Combining GIP and GLP-1 hormones (as seen in drugs like tirzepatide) is more effective for weight loss than GLP-1 alone, likely because they work together synergistically. However, the exact way this works in humans is still debated, as animal studies do not perfectly predict human biology.

GIPR antagonism reduces body weight in preclinical models by restoring leptin sensitivity, thereby reducing appetite.

Blocking GIP receptors can help obese individuals lose weight by making their bodies more sensitive to leptin, the hormone that signals fullness. This is currently only proven in animal models.

Sustained high-protein diets (HPD) exceeding 1.5 g/kg/day, particularly when consumed by athletes and bodybuilders, induce glomerular hyperfiltration and progressive glomerulosclerosis, leading to a rapid decline in kidney function and potential end-stage kidney disease.

If you are an athlete or bodybuilder, consuming protein levels significantly above 1.6 g/kg/day (often 3-4 g/kg/day) does not build more muscle but may accelerate kidney damage, especially if you have any underlying kidney issues. Monitor your kidney function regularly and consider reducing protein intake to the 1.6 g/kg/day range to maximize muscle gains while minimizing renal risk.

GLP-1 receptor agonists (semaglutide, tirzepatide) are effective for weight loss in the general population but demonstrate attenuated efficacy and unclear safety profiles specifically in breast cancer patients, particularly those receiving endocrine therapy.

If you have breast cancer and are taking hormonal therapy (like aromatase inhibitors), GLP-1 drugs like Semaglutide or Tirzepatide will likely help you lose weight, but not as much as they do for people without cancer. You should expect roughly half the weight loss seen in the general population. Discuss this with your oncologist, as safety data in your specific group is still being gathered.

Duodenal mucosal ablation (DMR) significantly reduces HbA1c in patients with Type 2 Diabetes, particularly those with high fasting glucose or insulin-requiring disease, by targeting the proximal small bowel to mimic the metabolic effects of bariatric surgery.

If you have Type 2 Diabetes and struggle to control your blood sugar with diet and medication, especially if you require insulin or have high fasting glucose, ask your doctor about Duodenal Mucosal Resurfacing (DMR). This is a minimally invasive endoscopic procedure that ablates a small section of your small intestine to improve how your body handles glucose. It is not a weight-loss surgery, but it can significantly lower your HbA1c and potentially reduce or eliminate your need for insulin. While it is a one-time procedure, it carries risks like stricture formation, so it is best considered for patients who have not responded to other treatments.

Roux-en-Y gastric bypass (RYGB) induces significant remission of Type 2 Diabetes (T2DM) and Systemic Arterial Hypertension (SAH) in obese patients, largely through neuroendocrine mechanisms involving GLP-1 and bile acids, independent of or in addition to weight loss.

For obese patients with difficult-to-control diabetes or hypertension, Roux-en-Y gastric bypass is a highly effective treatment that can lead to disease remission. This benefit is driven by hormonal changes in the gut (GLP-1 and bile acids) that improve metabolic control, not just by weight loss. While lifestyle changes are the first line of defense, they often fail to sustain control, making surgery a viable option for eligible candidates.

The ketone body β-hydroxybutyrate (βHB) inhibits glucose-induced GLP-1 secretion in enteroendocrine cells, with human jejunal enteroids showing sensitivity at much lower doses (10 mM) than murine cell lines (100 mM).

This research suggests that high concentrations of ketone bodies in the gut can suppress the release of GLP-1, a hormone that helps manage blood sugar and signals fullness. While this is a laboratory finding using human gut cells, it implies that metabolic states with high local ketone production (such as during fasting or specific dietary patterns) might alter how your body responds to carbohydrates by reducing this specific hormonal signal.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of adverse events compared to non-GLP-1RA antiobesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like semaglutide or liraglutide) for weight regain, current data suggests they are not more likely to cause adverse events than older weight loss medications. However, the study notes that starting these medications more than 12 months after surgery is associated with a significantly lower risk of adverse events compared to starting them within the first year.

Tirzepatide is associated with a higher likelihood of gastrointestinal adverse events compared to other GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, and exenatide).

If you take tirzepatide, expect gastrointestinal issues like nausea or vomiting more often than with other GLP-1 drugs. These are usually mild and go away, but they are the most common reason people stop the medication. Monitor your symptoms and report them.

Oral delivery of GLP-1 analogs (semaglutide, exenatide, dulaglutide) using liposomes containing tetraether lipids (TELs) and cell-penetrating peptides (CPPs) significantly increases cellular uptake in intestinal epithelial models compared to free peptides or conventional liposomes.

This research suggests a promising future where GLP-1 drugs (like Ozempic or Wegovy) could be taken orally using advanced liposome technology, potentially replacing injections. Currently, this is pre-clinical data showing high uptake in cell models, not a available product.

Acute L-arginine supplementation (6–8 g) taken 60–90 minutes before strength training provides no ergogenic effect on muscular endurance, peak torque, or resistance rate.

Do not take L-arginine specifically to boost your strength training performance. Taking 6-8 grams an hour before lifting does not increase your strength, endurance, or muscle growth compared to a placebo. While it may increase blood flow, this does not help you lift more weight or do more reps.